(300 WORDS MAX.) This proposal seeks to develop evaluate an orally active bioavailable metal attenuating compound for the treatment of Alzheimer's disease. The proposed drug development program is based on compounds previously developed in our laboratory and will be evaluated for ability to attenuate redox metal reactivity, protect human cells from oxidative damage, and ameliorate neuropathology in Alzheimer's disease transgenic mice. The compounds developed in this proposal will not only lead to potential drugs to treat Alzheimer's disease, but also provide powerful research tools for investigating specific pathogenic mechanisms that lead to Alzheimer'S disease and other age-related neurodegenerative disorders.